Team:Ciencias-UNAM/Achievements

From 2013.igem.org

(Difference between revisions)
(Created page with "<html> <head> <title>Achievements</title> <meta http-equiv="content-type" content="text/html; charset=utf-8"/> <meta http-equiv="imagetoolbar" content="no"/> <meta name="app...")
Line 391: Line 391:
<div id="u47_rtf"><p style="text-align:left;"><span style="font-family:Arial;font-size:20px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">Achievements</span></p><p align="justify">
<div id="u47_rtf"><p style="text-align:left;"><span style="font-family:Arial;font-size:20px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">Achievements</span></p><p align="justify">
<p><span style="font-family:Arial;font-size:14px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">Do the biological materials used in your lab work pose any of the following risks?</span></p>
<p><span style="font-family:Arial;font-size:14px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">Do the biological materials used in your lab work pose any of the following risks?</span></p>
-
<span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:italic;text-decoration:none;color:#666666;">Risks to the safety and health of team members or others working in the lab?</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"> No the lab is a regular educational and basic investigation laboratory.
+
<span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:italic;text-decoration:none;color:#666666;">Risks to the safety and health of team members or others working in the lab?</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"><br> We characterised LL-37 antimicrobial peptide from Team Trieste 2008. They used Lac promoter to express this peptide, hoping to inhibit cell growth. They did not have positive results, as the control experiment growth the same way as the one with LL-37 expression with IPTG. We approached this problem with two solutions. The first problem we saw in Trieste's characterisation was that Lac promoter has a very high basal level of transcription. Given pSB1C3 has a high copy number, it is transcribing a high amount of LL-37, still with no IPTG in the media. This could mean that there is selection pressure on E. coli to loose the plasmid, which could be one of the reasons the did not see changes between the control cells and the cells under IPTG induction. We addressed this problem by changing the promoter, constructing device BBa_K1230007. This device is under the pBad promoter, which works with arabinose. This promoter has a basal level of almost 0, so we are sure that it is not transcribing any LL-37 that could be making the cells to loose the plasmid. The second problem we addressed was the change in the codon usage they used. By changing the codons to produce more peptide in E. coli, the peptide may not have sufficient time to fold properly, altering it's function. We solved this problem by using the normal codon usage of this peptide, allowing it to fold properly into it's final conformation.
-
</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:italic;text-decoration:none;color:#666666;">Risks to the safety and health of the general public, if released by design or by accident?</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"> No, as all the strains are non-pathogenic if there was a release of them it would not cause any harm. Also the sequences used for the design are from other non-pathogenic strains and the product of them are not harmful separately or the construction itself.
+
-
</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:italic;text-decoration:none;color:#666666;">Risks to the environment, if released by design or by accident?</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;">The possible risk for the environment would be against pathogenic strains due our design. Nevertheless, considering the probabilities for our design to be expressed outside laboratory conditions, we do not think there would be any risk to the environment.
+
-
</span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:italic;text-decoration:none;color:#666666;">Risks to security through malicious misuse by individuals, groups, or countries?
+
-
</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;">The device itself does not contain any harmful DNA sequence, and as our strains are non-pathogenic ones could not be used for malicious misuse.
+
-
</span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p align="justify"><span style="font-family:Arial;font-size:14px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">If your project moved from a small-scale lab study to become widely used as a commercial/industrial product, what new risks might arise?</span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;">As our device is meant against pathogenic strains if it would become an industrial Project. We should first analyze the possible risks for being used in humans</span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:14px;font-weight:bold;font-style:normal;text-decoration:none;color:#666666;">What safety training have you received (or plan to receive in the future)? and under what biosafety provisions will / do you work? </span><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;"></span></p><p align="justify"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;">Our formation about safety comes from working in laboratories with a BioSafety level number 1, if we may work in the future in a laboratory with a different BioSafety level then we should get trained. The UNAM School of Science follows the biosafety regulations from the UNAM and in particular the recommendations made by the Environmental Management Unit. A more detailed protocol can be found at <b>(www.biomedicas.unam.mx/_administracion/_unidades_apoyo_inst/ manual_bioseguridad.pdf)</b>. Mexican regulations about biosafety are summarized at <b>http://amexbio.org/links.html</b>  According to WHO Biosafety manual our lab and our chassis is rated as Biosafety level 1.
+
<br><br>
<br><br>
-
The part is the human cathelicidin LL-37. The part is the BBa_K1230001 ( http://parts.igem.org/Part:BBa_K1230001). The human peptide LL-37 is a cationic antimicrobial peptide with activity against Gram-negative and Gram-positive bacteria. It has been shown to protect against Helicobacter pylori infection and its related gastritis, besides of inhibiting the growth of other pathogenic bacteria in the gastrointestinal tract such as Salmonella typhimurium and Escherichia coli.  
+
The principal aim of our project was to collaborate as much as possible to the iGEM mission to develop science freely. The parts we designed followed this principle, by being useful in very aspects, apart of our own project. We developed a Multiple Antibiotic Resistance protein, which acts as a transcriptional activator in E. coli, it allows the expression of the acrAB and tolC operons, which activate the AcrAB-TolC efflux pump, a mechanism that has been related with resistance to organic solvents, dyes, detergents, antibiotics such as chloramphenicol, tetracycline, novobiocin, erythromycin, fusidic acid and cloxacillin, as well as to cationic antimicrobial peptides, such as LL-37, HNP-2 and HBD-1. This part can be used in several ways in different iGEM projects. We also sent to the parts registry the LL-37 peptide, with adequate codon usage, an improvement on part BBa_K875000, that allows LL-37 expression. <br><br>
-
We are using it because we want our synthetic bacteria to express the LL-37 antimicrobial peptide in presence of pathogenic bacteria that express quorum sensing molecule AI-2.
+
As part of our collection, we also designed the device BBa_K1230009, which is the promoter as well as the coding sequence for the repressor AraC which is transcribed in the opposite direction, with the Elowitz repressilator. This part will allow an easy way to produce proteins by Arabinose induction, improving the way characterization is made on iGEM.
-
<br><br>
+
</span></p>
-
There is no potential safety/health risk for the team members, institution staff or general public by using the part that codes for de LL-37 antimicrobial peptide because is a human gene that is express only when the inmmune system interacts with a pathogenic microbe like Helicobacter pylori.
+
-
<br><br
+
-
The part is NOT listed under the Australia Group guidelines. The safety level of the lab was the BSL1 as the the strains and the coding regions used are non pathogenic and non potentially phatogenical when transcribed by our chassis organism.
+
-
</span></p><p style="text-align:left;"><span style="font-family:Arial;font-size:13px;font-weight:normal;font-style:normal;text-decoration:none;color:#666666;text-decoration:none;">&nbsp;</span></p></div>
+
-
 
+
</div>
</div>

Revision as of 02:47, 28 September 2013

Achievements

HOME

PROJECT

HUMAN PRACTICES

TEAM

ACHIEVEMENTS

Home > Achievements

Achievements

Do the biological materials used in your lab work pose any of the following risks?

Risks to the safety and health of team members or others working in the lab?


We characterised LL-37 antimicrobial peptide from Team Trieste 2008. They used Lac promoter to express this peptide, hoping to inhibit cell growth. They did not have positive results, as the control experiment growth the same way as the one with LL-37 expression with IPTG. We approached this problem with two solutions. The first problem we saw in Trieste's characterisation was that Lac promoter has a very high basal level of transcription. Given pSB1C3 has a high copy number, it is transcribing a high amount of LL-37, still with no IPTG in the media. This could mean that there is selection pressure on E. coli to loose the plasmid, which could be one of the reasons the did not see changes between the control cells and the cells under IPTG induction. We addressed this problem by changing the promoter, constructing device BBa_K1230007. This device is under the pBad promoter, which works with arabinose. This promoter has a basal level of almost 0, so we are sure that it is not transcribing any LL-37 that could be making the cells to loose the plasmid. The second problem we addressed was the change in the codon usage they used. By changing the codons to produce more peptide in E. coli, the peptide may not have sufficient time to fold properly, altering it's function. We solved this problem by using the normal codon usage of this peptide, allowing it to fold properly into it's final conformation.

The principal aim of our project was to collaborate as much as possible to the iGEM mission to develop science freely. The parts we designed followed this principle, by being useful in very aspects, apart of our own project. We developed a Multiple Antibiotic Resistance protein, which acts as a transcriptional activator in E. coli, it allows the expression of the acrAB and tolC operons, which activate the AcrAB-TolC efflux pump, a mechanism that has been related with resistance to organic solvents, dyes, detergents, antibiotics such as chloramphenicol, tetracycline, novobiocin, erythromycin, fusidic acid and cloxacillin, as well as to cationic antimicrobial peptides, such as LL-37, HNP-2 and HBD-1. This part can be used in several ways in different iGEM projects. We also sent to the parts registry the LL-37 peptide, with adequate codon usage, an improvement on part BBa_K875000, that allows LL-37 expression.

As part of our collection, we also designed the device BBa_K1230009, which is the promoter as well as the coding sequence for the repressor AraC which is transcribed in the opposite direction, with the Elowitz repressilator. This part will allow an easy way to produce proteins by Arabinose induction, improving the way characterization is made on iGEM.